European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-06-18

OncoTrack - Methods for systematic next generation oncology biomarker development

Objetivo

We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same patients. This will be complemented by the development and application of highly sensitive techniques to identify individual mutations, transcripts and proteins/protein complexes both in-situ in pathology slides as well as in patients’ blood or serum. The integration of these results will allow us to address the heterogeneity of the tumor samples, to deduce the genome/epigenome/transcriptome of the different cell types making up or originating from the tumor (e.g. circulating tumor cells, tumour stem cells or xenografts), to establish models able to predict suitable candidates for further biomarker development, and also to predict the effects and side effects of drugs in the treatment of genetically defined groups of patients. Available biomarkers, as well as biomarkers predicted from the work within the project will be validated in patient derived xenograft models and stem cell cultures, and ultimately transferred into a point of care (POC) diagnostic format. In parallel we will explore the use of the global genome and methylome information, e.g. derived from the analysis of free tumor DNA in the serum of the patient, as the ‘ultimate’ biomarker, to model the biology of the tumor (possibly even before any tumor has been localised), and as an independent route to predict clinically relevant parameters. Though sequencing/methylation analysis of the genome of the tumor through free DNA is currently still too costly for use as a routine diagnostic, this is likely to change over the period covered by the grant, due to the extremely rapid progress in the development of large scale sequencing techniques.

Ámbito científico

Programa(s)

Tema(s)

Convocatoria de propuestas

IMI-JU-02-2009
Consulte otros proyectos de esta convocatoria

Régimen de financiación

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Coordinador

Bayer Pharma AG
Aportación de la UE
Sin datos
Dirección
Muellerstrasse 178
13353 Berlin
Alemania

Ver en el mapa
Región
Berlin Berlin Berlin
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Burkhardt Neumann (Mr.)
Investigador principal
David Henderson (Dr.)
Enlaces
Coste total
Sin datos

Participantes (21)

Compartir esta página

Descargar

Última actualización: 12 Abril 2022

Mi folleto

Permalink: https://cordis.europa.eu/project/id/115234/es

European Union, 2024